Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada

View Full Paper
Ask AI
Bookmark
Share

Authors

CZCraig Zimmerman

Discussion

Loading...

Member takes

Overview

Assessment reveals varied incidence and prevalence of essential thrombocythemia patients eligible for cytoreductive therapies across US health plans, suggesting implications for treatment access.

Key Points

  • Prevalence of essential thrombocythemia indicates significant variability across health plans, affecting treatment eligibility.
  • Medical costs for individuals with myeloproliferative neoplasms are notably higher, underscoring economic strain on healthcare systems.
  • Cytoreductive therapies are essential for managing thromboembolic events in eligible patients with elevated incidence rates.
  • Health plans in the US and Canada demonstrate differing coverage and access to necessary therapies for essential thrombocythemia patients.

Cite This Study

Craig Zimmerman (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc3bhttps://doi.org/10.1182/blood-2025-8199
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data2025
  2. 2Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans2025
  3. 3Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.2025
  4. 4Impact of essential thrombocythemia on in-hospital outcomes and thrombotic complications in patients hospitalized with COVID-19: A national inpatient sample analysis (2016–2022)2025
  5. 5Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2− Early Breast Cancer in the Real-World Setting2025